Sei Investments Co. raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 75.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,933 shares of the medical device company’s stock after purchasing an additional 2,983 shares during the period. Sei Investments Co.’s holdings in AtriCure were worth $168,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN raised its position in AtriCure by 131.9% during the 1st quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock valued at $2,145,000 after purchasing an additional 63,711 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in AtriCure during the 1st quarter valued at approximately $329,000. Bank of Montreal Can raised its position in AtriCure by 1.2% during the 1st quarter. Bank of Montreal Can now owns 10,462 shares of the medical device company’s stock valued at $200,000 after purchasing an additional 128 shares during the last quarter. Swiss National Bank raised its position in AtriCure by 7.0% during the 1st quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock valued at $1,048,000 after purchasing an additional 3,600 shares during the last quarter. Finally, Keybank National Association OH raised its position in AtriCure by 5.1% during the 1st quarter. Keybank National Association OH now owns 38,902 shares of the medical device company’s stock valued at $745,000 after purchasing an additional 1,905 shares during the last quarter. 82.07% of the stock is owned by institutional investors and hedge funds.
AtriCure, Inc. (NASDAQ ATRC) opened at 20.00 on Tuesday. The firm’s 50 day moving average price is $22.42 and its 200-day moving average price is $21.34. AtriCure, Inc. has a 12-month low of $14.78 and a 12-month high of $25.18. The stock’s market cap is $686.68 million.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.05. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The firm had revenue of $45.23 million during the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The company’s revenue was up 14.0% on a year-over-year basis. Equities research analysts anticipate that AtriCure, Inc. will post ($0.95) earnings per share for the current fiscal year.
In other news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $22.40, for a total transaction of $224,000.00. Following the completion of the sale, the director now owns 29,967 shares of the company’s stock, valued at $671,260.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.00% of the company’s stock.
ATRC has been the subject of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $25.00 price target on shares of AtriCure in a research report on Sunday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price target (up previously from $25.00) on shares of AtriCure in a research report on Friday, July 28th. BidaskClub lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. TheStreet raised AtriCure from a “d+” rating to a “c-” rating in a research report on Monday, May 15th. Finally, ValuEngine raised AtriCure from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $25.00.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/09/12/atricure-inc-atrc-holdings-lifted-by-sei-investments-co.html.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.